Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 32416072

Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
Lancet Oncol
Publication date
2020 Jun
First author
Abou-Alfa GK

This record carries publication-notice metadata. Review the notices below before relying on it.

Publication notices

absence is not clearance
true
has correction metadata
true
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet Oncol. 2020 Jun;21(6):738-739. doi: 10.1016/S1470-2045(20)30214-X.
    note
    Source null
    related pmid
    32416071
    relationship
    Comment in
  2. citation
    Lancet Oncol. 2020 Aug;21(8):e370. doi: 10.1016/S1470-2045(20)30343-0.
    note
    Source null
    related pmid
    32758465
    relationship
    Comment in
  3. citation
    Lancet Oncol. 2020 Aug;21(8):e371. doi: 10.1016/S1470-2045(20)30394-6.
    note
    Source null
    related pmid
    32758466
    relationship
    Comment in
  4. citation
    Lancet Oncol. 2020 Oct;21(10):e462. doi: 10.1016/S1470-2045(20)30547-7.
    note
    Source null
    related pmid
    33002440
    relationship
    Erratum in
  5. citation
    Lancet Oncol. 2024 Feb;25(2):e61. doi: 10.1016/S1470-2045(24)00013-5.
    note
    Source null
    related pmid
    38301702
    relationship
    Erratum in

Authors and identifiers

  1. name
    Abou-Alfa GK
    type
    Author
  2. name
    Macarulla T
    type
    Author
  3. name
    Javle MM
    type
    Author
  4. name
    Kelley RK
    type
    Author
  5. name
    Lubner SJ
    type
    Author
  6. name
    Adeva J
    type
    Author
  7. name
    Cleary JM
    type
    Author
  8. name
    Catenacci DV
    type
    Author
  9. name
    Borad MJ
    type
    Author
  10. name
    Bridgewater J
    type
    Author
  11. name
    Harris WP
    type
    Author
  12. name
    Murphy AG
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    Abou-Alfa GK
    type
    Author
  2. name
    Macarulla T
    type
    Author
  3. name
    Javle MM
    type
    Author
  4. name
    Kelley RK
    type
    Author
  5. name
    Lubner SJ
    type
    Author
  6. name
    Adeva J
    type
    Author
  7. name
    Cleary JM
    type
    Author
  8. name
    Catenacci DV
    type
    Author
  9. name
    Borad MJ
    type
    Author
  10. name
    Bridgewater J
    type
    Author
  11. name
    Harris WP
    type
    Author
  12. name
    Murphy AG
    type
    Author
bibliography ids
  1. nci-bib-40c0486461fccf5f3507a2da
book metadata
content sha256
977d748a7216a98823ad7b46a61cbd166a082328dccd394102ef858ed1503de2
document type
citation
dois
  1. 10.1016/S1470-2045(20)30157-1
electronic publication date
display
2020 May 13
precision
day
year
2020
evidence scope
bibliographic_metadata_only
id
pubmed:32416072
immutable id
pubmed:32416072@977d748a7216a98823ad7b46a61cbd166a082328dccd394102ef858ed1503de2
journal
abbreviation
Lancet Oncol
issn electronic
1474-5488
issn print
1470-2045
issue
6
name
The Lancet. Oncology
nlm unique id
100957246
pages
796-807
volume
21
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
true
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet Oncol. 2020 Jun;21(6):738-739. doi: 10.1016/S1470-2045(20)30214-X.
    note
    Source null
    related pmid
    32416071
    relationship
    Comment in
  2. citation
    Lancet Oncol. 2020 Aug;21(8):e370. doi: 10.1016/S1470-2045(20)30343-0.
    note
    Source null
    related pmid
    32758465
    relationship
    Comment in
  3. citation
    Lancet Oncol. 2020 Aug;21(8):e371. doi: 10.1016/S1470-2045(20)30394-6.
    note
    Source null
    related pmid
    32758466
    relationship
    Comment in
  4. citation
    Lancet Oncol. 2020 Oct;21(10):e462. doi: 10.1016/S1470-2045(20)30547-7.
    note
    Source null
    related pmid
    33002440
    relationship
    Erratum in
  5. citation
    Lancet Oncol. 2024 Feb;25(2):e61. doi: 10.1016/S1470-2045(24)00013-5.
    note
    Source null
    related pmid
    38301702
    relationship
    Erratum in
outcomes validated
false
pmid
32416072
provenance
batch id
40d9eae1f1d369f13109
provider
NCBI PubMed ESummary
record sha256
d3b880fe1ab208f0072c2b64b00ff1306232c9f671115c6c8579203ca79aaba3
response sha256
03fa1567b6babd78281d8ec4529596b9d4953c2c4ac23257dca371d609645ba9
retrieved at
2026-09-09T23:47:52.637547+00:00
publication date
display
2020 Jun
precision
month
year
2020
publication types
  1. Clinical Trial, Phase III
  2. Journal Article
  3. Multicenter Study
  4. Randomized Controlled Trial
  5. Research Support, Non-U.S. Gov't
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/32416072/
title
Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study.

Preserved source evidence · Not medical advice